Articles tagged with Cannabinoids
Researchers propose using carefully designed combinations of approved drugs to create a more convincing placebo, limiting participant disclosure, and rigorous testing to ensure effective masking. This approach, called UMBRAA, aims to overcome the challenge of distinguishing between psychedelic effects and the power of expectation.
Researchers found that hemp-derived cannabinoid brands emphasize lifestyle and recreational marketing, with minimal attention to safety warnings, on social media platforms. The study highlights gaps in platform policies and enforcement, calling for clearer standards addressing youth-oriented features and misleading health claims.
A review of cannabis and cannabinoids' therapeutic use reveals potential health benefits while emphasizing the need for risk assessment and harm reduction strategies. The study highlights the importance of evidence-based guidelines for safe and effective treatment.
Researchers at Charité – Universitätsmedizin Berlin investigated the use of THC to alleviate PTSD-related nightmares. The study found that more than half of participants responded to treatment, with over a third experiencing complete disappearance of nightmares. The medication was also well-tolerated, with moderate side effects reported.
A study identified alterations in the endocannabinoid system associated with severe acute pancreatitis, including decreased circulating levels of 2-AG. Restoring 2-AG levels reduced inflammation and lung damage, highlighting the system's role in the disease's pathophysiology.
Researchers have identified potential mechanisms linked to reduced type 2 diabetes risk in chronic cannabis users. A team led by Nicholas V. DiPatrizio found that specific compounds within cannabis regulate metabolism, leading to significant weight loss and improved glucose regulation in obese mice.
A study by University of Utah Health found that older adults use cannabis edibles for non-psychoactive effects, seeking better quality of life. Many participants were influenced by positive anecdotes from friends or family members, highlighting the importance of word of mouth in their decision-making process.
Dr. Gobbi challenges the global drug-development system, stating that promising treatments for mental illness are failing to reach patients due to venture capital and profit motives. Her research focuses on cannabis, melatonin, and psychedelics, with a goal of improving public-health decisions and treatment outcomes.
A recent study found that delta-8 THC products often lack clear and consistent labeling, with high doses found in products marketed to youth. The study highlights concerns for consumer safety, as the products are subject to fewer regulations than medical and recreational cannabis.
Researchers discovered that CBD and CBG can significantly reduce liver fat and improve metabolic health by creating a backup energy reserve and restoring cellular cleaning crews. These compounds also showed promising effects on treating metabolic diseases, including reducing body fat mass and improving insulin sensitivity.
An updated Cochrane review of 21 clinical trials involving over 2,100 adults found no high-quality evidence that cannabis-based medicines reduce neuropathic pain more than placebo. Small improvements were reported by patients using products with both THC and CBD, but these changes were not clinically meaningful.
A preclinical study shows that cannabidiol restores emotional behavior, reduces alcohol-related vulnerability, and reverses gut microbiota alterations caused by prenatal alcohol exposure. Female mice particularly benefited from CBD treatment, which normalized their emotional alterations and eliminated vulnerability to alcohol addiction.
The funding will support research at UCLA's David Geffen School of Medicine, College of Letters and Science, and Fielding School of Public Health. The studies aim to inform evidence-based regulation and public health priorities.
A systematic review found that cannabis products with higher THC concentration provide small improvements in pain and function, but at the cost of increased risks of common adverse events. CBD-only formulations showed no benefits. Long-term research is needed to guide patients and policymakers.
A new study used deep learning and large-scale computer simulations to identify structural differences in synthetic cannabinoid molecules that cause them to bind to human brain receptors differently from classical cannabinoids. Researchers found that these substances often trigger the beta arrestin pathway, leading to more severe psych...
A recent study found that dogs given CBD supplements show below-average levels of aggression over time, with the most aggressive changes observed in male dogs. The study, which used data from almost 50,000 dog owners, also found a link between CBD use and health conditions such as dementia and osteoarthritis.
A new study from Texas Biomedical Research Institute found that low-dose THC significantly reduced side effects and inflammation caused by HIV and antiretroviral therapy. The treatment also increased serotonin levels, lowered cholesterol and toxic bile acids, and improved cardiovascular health.
Researchers developed a portable sensor to detect synthetic cannabinoids in e-cigarette liquids and biological fluids, allowing for early intervention and harm reduction. The device shows high selectivity and sensitivity, detecting concentrations as low as 0.2 µM and identifying specific peaks that quantify substances present.
Researchers explored the therapeutic potential of cannabidiol for Alzheimer's disease by assessing its effects on immune responses and neuroinflammation. CBD treatment reduced expression of key regulators for neuroinflammation in Alzheimer's mice, associated with less proinflammatory molecules.
Researchers manipulated the endocannabinoid signaling system in prenatal mice, leading to altered gene expression, neural properties, and social interaction deficits. This work suggests that prenatal manipulation of this system may lead to neuropsychiatric conditions, particularly those involving social deficits.
Polyphenols are multifunctional agents with anti-inflammatory, antioxidant, microbiota-modulating, and neuroprotective properties. The Polyphenols Applications 2025 congress explores novel applications of polyphenols in various fields.
A study found a significant increase in adolescent vaping of THC, CBD, and synthetic cannabinoids from 2021 to 2023. The prevalence of THC vaping peaked in 2022, while SCs continued to rise, with females having a higher rate of vaping these substances.
A controlled clinical trial found that two-thirds of participants showed behavioral improvements with CBD treatment, highlighting its potential benefits. However, the study also revealed a significant placebo effect, emphasizing the need for further research to fully understand CBD's therapeutic potential.
Researchers at Macquarie University have discovered that cannabis-derived compounds Cannabidiol (CBD) and Cannabidivarin (CBDV) are effective against a range of fungal pathogens, including Cryptococcus neoformans and dermatophytes. The findings open the door to possible new treatments for these fungal infections.
Researchers at Indiana University discovered a new way acetaminophen targets pain by inhibiting an enzyme that produces endocannabinoids. Reduced levels of these compounds may lead to decreased pain relief, providing a potential target for designing safer pain medications.
A meta-analysis of clinical trials found moderate improvements in social responsiveness and small reductions in disruptive behaviors when cannabidiol (CBD) cannabis extract was used to treat ASD. The therapy also showed a favorable safety profile with no significant increase in adverse events compared to placebo.
A recent study by the University of Arkansas System Division of Agriculture found that consumer understanding of CBD oils has not kept pace with their growth in the market. Consumers were often confused about product names, with full-spectrum CBD containing terpenes and up to 0.3% THC.
The American College of Physicians issues Best Practice Advice for managing chronic noncancer pain with cannabis or cannabinoids. For most patients, common treatments should be recommended first due to limited evidence and known harms associated with cannabis and cannabinoid products.
Scientists at the University of South Australia have developed a phospholipid complex to improve cannabidiol's effectiveness in treating epilepsy, multiple sclerosis, and other neurodegenerative diseases. The new formula increases cannabidiol's solubility by up to six times and improves its absorption in the gastrointestinal tract.
Researchers found that cannabidiol stimulates the biomineralization of teeth even under inflammatory conditions, promoting tissue repair. The substance also inhibited the synthesis of inflammatory mediators in macrophages, suggesting an anti-inflammatory effect.
A NIH-funded research team has engineered a medication that targets the body's cannabinoid receptor type 1 (CB1), which shows promise in treating acute and chronic pain. The new drug, VIP36, is more 'peripherally restricted' compared to previous drugs, reducing unwanted side effects.
Researchers developed a custom-designed compound that mimics natural cannabis molecules to alleviate chronic pain without psychoactive side effects. The modified synthetic cannabinoid compound showed promise as a nonaddictive pain reliever, offering prolonged relief and minimizing tolerance.
Researchers have discovered how a CBD compound can bind to cannabinoid receptors, mitigating the negative effects of THC on pain management while preserving its benefits. The study opens new avenues for harnessing THC's beneficial effects with reduced side effects.
A cross-sectional study found that children exposed to secondhand cannabis smoke at home have significantly higher urinary cannabinoid biomarker levels, indicating increased exposure to toxic and carcinogenic chemicals. Reducing in-home cannabis smoking can substantially reduce child exposure to these harmful substances.
Researchers at University of the Basque Country discover molecule that protects brain and reverses initial cognitive damage caused by dementia; increases activity of cannabinoid and cholinergic systems, improving memory. Further studies needed to identify similar molecules for clinical trials.
A new study explores whether CBD can reduce scan-related anxiety in advanced breast cancer patients, finding it was safe but did not significantly change anxiety levels. However, participants who consumed CBD experienced lower anxiety levels after treatment.
A randomized clinical trial found that cannabidiol (CBD) significantly reduced anxiety levels 2-4 hours after ingestion in women with advanced breast cancer. CBD's anxiolytic effect suggests its potential as a treatment for scan-related anxiety.
Researchers found that increasing levels of the naturally occurring endocannabinoid 2-AG can counteract the rewarding properties of opioids, reducing addiction-like behaviors in mice. The study suggests a potential new therapeutic strategy to alleviate pain while minimizing opioid addiction risk.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
A WVU research partnership with the DEA aims to improve fast and accurate identification of psychoactive substances like fentanyl. The Expert Algorithm for Substance Identification (EASI) will enable labs using different instruments to share data on chemical profiles, helping to identify drugs like fentanyl.
Research by the University of Sydney has identified CBN as a constituent that improves sleep in rats. The study showed that CBN increased both NREM and REM sleep, leading to increased total sleep time.
The number of seizures in US children due to medication or substance exposure has more than doubled between 2009 and 2023. The main culprits are over-the-counter antihistamines, prescription antidepressants, painkillers, and synthetic cannabinoids.
Researchers will examine cognitive and psychomotor functions to compare effects of CBD on driving performance between men and women. The five-year study aims to provide a comprehensive understanding of the substance's influence.
Researchers found that prenatal exposure to synthetic cannabinoid led to cardiovascular problems in female rats and increased respiratory sensitivity to carbon dioxide in male rats. Sleep quality also deteriorated in both sexes, with males experiencing sleep fragmentation due to frequent wakefulness episodes.
A study published in the journal Insects found that hemp leaf extract containing cannabidiol (CBD) is effective in killing mosquito larvae, including those resistant to typical insecticides. The research suggests CBD's potential as a safe and sustainable alternative for controlling mosquito populations.
A new study by UC Riverside demonstrates that calorie restriction does not significantly reduce voluntary exercise in mice. Researchers found that mice continued to run at similar levels regardless of the amount of food they ate, challenging the long-held belief that dieting drains workout energy. The study's findings have implications...
A new study found that Cannabigerol (CBG) significantly reduced feelings of anxiety at 20, 45 and 60 minutes after ingestion, with stress ratings also decreasing. CBG's effect on memory was unexpectedly positive, enhancing the ability to recall lists of words.
Research on mice exposes to cannabidiol during gestation shows altered behaviors and brain changes, affecting nerve cells involved in processing emotions. The study suggests a public health priority to understand CBD's impact on developing nervous systems.
Researchers found that five cannabis terpenes reduced chronic neuropathic pain levels comparable to morphine. The combination of terpenes and morphine enhanced pain relief without negative side effects. Terpenes offer an alternative to opioids for pain management with a better side effect profile.
A new study found that nearly 3% of healthy adolescents aged 11-15 have used commercial CBD products for medicinal or health-related reasons. The study identified predictors of commercial CBD use, including older age, certain health conditions, and parental attitudes towards cannabis use.
The Society for Academic Emergency Medicine (SAEM) has released a new guideline for managing nonopioid use disorders in emergency departments. The guidelines provide evidence-based recommendations for evaluating and treating conditions such as alcohol withdrawal syndrome, alcohol use disorder, and cannabinoid hyperemesis syndrome. The ...
A recent study found that breastfeeding mothers who use cannabis have detectable amounts of THC in their milk, even after 12 hours of abstinence. The amount of THC detected is low, but its impact on infants is unknown.
Scientists at Salk Institute explore the clinical potential of cannabinol (CBN) in treating traumatic brain injury, Alzheimer's disease, and Parkinson's disease. They identify four CBN analogs with improved neuroprotective ability and drug-like efficacy.
A new study found that non-medical cannabis use is significantly associated with a 96% decrease in odds of subjective cognitive decline. However, medical and dual-use were not significant in reducing the risk of SCD. The study highlights the potential protective effects of cannabis on cognition, but more longitudinal research is needed...
A recent study published in The Journal of Pain has found that CBD products are ineffective in reducing chronic pain and may pose health risks. The research, led by the University of Bath, examined existing studies on CBD and concluded that there is no quality evidence to support its use as a pain reliever.
Researchers found that CBD-dominant products reduced anxiety symptoms and improved mood without the intoxicating effects of THC. The study suggests that CBD may provide a safer alternative for treating anxiety disorders.
A new study published in the Journal of Dairy Science explores the use of spent hemp biomass as a feed ingredient for lactating dairy cows. The research shows that hemp biomass is safe and does not negatively affect milk production or animal health, despite being less palatable due to its characteristic smell. The study suggests potent...
A survey of 2,002 Danish dog owners found that 38% used cannabinoids, primarily CBD, to treat their pets' pain, behavioral issues, and allergies. 77% of these owners reported positive effects on their dogs' mental or physical health.
A recent study published in Sports Medicine found that cannabis users reported increased enjoyment and euphoria during exercise, with CBD seemingly having a greater impact on mood than THC. However, the use of cannabis before exercise was found to have no significant effect on performance.
A new U-M study found that 72% of adults in the US have heard of CBD, while fewer are aware of other hemp-derived cannabinoids like delta-8-THC and CBG. The products' lack of regulation and inadequate safety testing pose health risks to consumers, especially young people.